Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06117280 · ClinicalTrials.gov registry record · NA
Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus
A NA study of Energy and Focus, sponsored by Iovate Health Sciences International.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06117280: Completed NA study of Energy and Focus, sponsored by Iovate Health Sciences International.
NCT06117280 is a NA study of Energy and Focus that has completed, run by Iovate Health Sciences International. The registered enrollment target is 45 participants, below the 859-participant average among 7 other Energy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06117280, a NA study of Energy and Focus, has completed, sponsored by Iovate Health Sciences International.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PXN to a placebo control. Participants will abstain from caffeine for 3 days, before taking the first test/placebo product for 3 consecutive days. Participants will complete questionnaires at 30, 60, 90, and 120 minutes after ingestion on Day 1 and Day 3 of ingestion. Participants will have a 3-day washout period before trialing the next test product/placebo.
Primary Outcome
Participants will independently complete a cognitive assessment battery at home on their computer or tablet. "Double Trouble" is a 90-second timed test. Based on a classic Stroop test, Double Trouble measures selective attention, processing speed, and the brain's ability to focus on specific information when presented with conflicting and layered stimuli.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Paraxanthine 200 mg
- OTHER Paraxanthine 300 mg
Study Locations (1)
California
- Citruslabs - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2023-10-20 |
| Phase | NA |
What the finished NCT06117280 record still lists
NCT06117280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 859-participant average among 7 other Energy trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Energy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06117280 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06117280 about?
NCT06117280 is a clinical study titled "Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus". Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PX...
What is the current status of trial NCT06117280?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2023-07-18. Estimated completion is 2023-10-20.
What conditions does trial NCT06117280 study?
This clinical trial studies the following conditions: Energy, Focus, Caffeine Withdrawal.
What interventions are being tested in trial NCT06117280?
The interventions under investigation include: Placebo (OTHER), Paraxanthine 200 mg (OTHER), Paraxanthine 300 mg (OTHER).
Who is sponsoring clinical trial NCT06117280?
This trial is sponsored by Iovate Health Sciences International, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06117280 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Energy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Heart & Soil's Lifeblood on Iron and Energy Levels
RECRUITING · NA
-
Effects of Dynamine Ingestion on Various Indices of Sustained Energy
COMPLETED · NA
-
Radicle Energy 24: A Study of Health and Wellness Products on Fatigue and Related Health Outcomes
COMPLETED · NA
-
Evaluating the Effects of Snack Products on Energy
COMPLETED · NA
-
The Acute Effects of Liquid IV's Pre-Workout Supplement on Muscle Endurance & Strength, Energy, and Cognition
COMPLETED · NA
-
Alii Supplement Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI